Tempus AI, Inc. Class A Common Stock Cash Flow Conversion Efficiency
Tempus AI, Inc. Class A Common Stock cash flow conversion efficiency. Based on the latest financial reports, Tempus AI, Inc. Class A Common Stock (TEM) has a cash flow conversion efficiency ratio of -0.017x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.53 Million) by net assets ($444.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tempus AI, Inc. Class A Common Stock (2019–2025)
Cash flow conversion efficiency of Tempus AI, Inc. Class A Common Stock from 2019 to 2025. This chart illustrates how Tempus AI, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TEM stock price and chart for real-time trading data and today's change.
Tempus AI, Inc. Class A Common Stock Cash Flow Conversion Ratio Explained
Tempus AI, Inc. Class A Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tempus AI, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tempus AI, Inc. Class A Common Stock ranked by their cash flow conversion efficiency. Also see market value of Tempus AI, Inc. Class A Common Stock for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mankind Pharma Ltd
NSE:MANKIND
|
0.099x |
|
Covestro AG
XETRA:1COV
|
0.048x |
|
LLOYDS METALS AND ENERGY LTD.
NSE:LLOYDSME
|
-0.114x |
|
COVESTRO AG SP.ADR 1/2
F:1CO1
|
0.043x |
|
WOORI FIN. GRP SP.ADR/3
F:2WGA
|
0.311x |
|
Elanco Animal Health
NYSE:ELAN
|
0.044x |
|
CSPC PHARMACEUT.GR. ADR4
F:CVGU
|
N/A |
|
Align Technology Inc
NASDAQ:ALGN
|
0.036x |
Annual Cash Flow Conversion Efficiency for Tempus AI, Inc. Class A Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tempus AI, Inc. Class A Common Stock from 2019 to 2025. Review Tempus AI, Inc. Class A Common Stock free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $491.33 Million | $-218.09 Million | -0.444x | +86.77% |
| 2024-12-31 | $56.34 Million | $-189.04 Million | -3.355x | -2263.79% |
| 2023-12-31 | $-1.38 Billion | $-214.34 Million | 0.155x | +4.09% |
| 2022-12-31 | $-1.13 Billion | $-168.20 Million | 0.149x | -43.25% |
| 2021-12-31 | $-807.49 Million | $-211.98 Million | 0.263x | -34.80% |
| 2020-12-31 | $-512.98 Million | $-206.56 Million | 0.403x | -12.52% |
| 2019-12-31 | $-254.41 Million | $-117.11 Million | 0.460x | -- |
About Tempus AI, Inc. Class A Common Stock
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnosti… Read more